Figures & data
Figure 1 Lesion size measurement by MRI. (A) Unidimensional measurement of tumor long axis diameter. (B) Bidimensional measurement of tumor long and short axis diameters. (C) Three-dimensional measurement of tumor volume.
![Figure 1 Lesion size measurement by MRI. (A) Unidimensional measurement of tumor long axis diameter. (B) Bidimensional measurement of tumor long and short axis diameters. (C) Three-dimensional measurement of tumor volume.](/cms/asset/c8f61841-5cbd-48d1-983d-63ee114566e6/dbct_a_23154619_f0001_b.jpg)
Figure 2 Fully quantitative DCE-MRI analysis in a breast cancer patient undergoing NAT. (A) Pretreatment DCE-MRI analysis yields a baseline calculated mean tumor Ktrans value of 0.3 min−1. (B) DCE-MRI analysis after one cycle of NAT yields a calculated mean tumor Ktrans value of 0.2 min−1. (C) Imaging after completion of NAT shows that the lesion is no longer visible; at surgery, the patient had a pathologic complete response.
Abbreviations: DCE-MRI, dynamic contrast-enhanced magnetic resonance imaging; NAT, neoadjuvant therapy; Ktrans, volume transfer constant.
![Figure 2 Fully quantitative DCE-MRI analysis in a breast cancer patient undergoing NAT. (A) Pretreatment DCE-MRI analysis yields a baseline calculated mean tumor Ktrans value of 0.3 min−1. (B) DCE-MRI analysis after one cycle of NAT yields a calculated mean tumor Ktrans value of 0.2 min−1. (C) Imaging after completion of NAT shows that the lesion is no longer visible; at surgery, the patient had a pathologic complete response.](/cms/asset/de731e74-9716-462a-bdc5-c9a456b7fac0/dbct_a_23154619_f0002_c.jpg)
Figure 3 DW-MRI in a breast cancer patient undergoing NAT. (A) On a pretreatment image with no diffusion gradient (ie, b = 0 s/mm2), the tumor is difficult to distinguish from background normal parenchyma. (B) Pretreatment diffusion-weighted image (b = 660 s/mm2) demonstrates subtle patchy increased signal in the deep upper breast, corresponding to an infiltrative tumor. (C) Pretreatment quantitative ADC map, with color-coded voxels corresponding to tissue ADC. The tumor region is outlined in white. (D) ADC map derived from DW-MRI after one cycle of NAT; the tumor volume (again outlined in white) has markedly decreased.
Abbreviations: DW-MRI, diffusion-weighted magnetic resonance imaging; NAT, neoadjuvant therapy; ADC, apparent diffusion coefficient.
![Figure 3 DW-MRI in a breast cancer patient undergoing NAT. (A) On a pretreatment image with no diffusion gradient (ie, b = 0 s/mm2), the tumor is difficult to distinguish from background normal parenchyma. (B) Pretreatment diffusion-weighted image (b = 660 s/mm2) demonstrates subtle patchy increased signal in the deep upper breast, corresponding to an infiltrative tumor. (C) Pretreatment quantitative ADC map, with color-coded voxels corresponding to tissue ADC. The tumor region is outlined in white. (D) ADC map derived from DW-MRI after one cycle of NAT; the tumor volume (again outlined in white) has markedly decreased.](/cms/asset/53a2d5fd-34c0-4bee-acd6-8810d2f6904a/dbct_a_23154619_f0003_c.jpg)
Figure 4 MT results from a healthy volunteer. (A) MToff. (B) MTon. (C) MTR map demonstrating an average 40% reduction in signal (ie, MTR = 0.4) in the fibroglandular tissue with good fat suppression.
![Figure 4 MT results from a healthy volunteer. (A) MToff. (B) MTon. (C) MTR map demonstrating an average 40% reduction in signal (ie, MTR = 0.4) in the fibroglandular tissue with good fat suppression.](/cms/asset/e83866dc-4ba9-4ce3-950b-d520588fab98/dbct_a_23154619_f0004_c.jpg)
Figure 5 General pulse sequence diagram for a CEST MRI experiment.
Abbreviations: CEST MRI, chemical exchange saturation transfer magnetic resonance imaging; RF, radiofrequency.
![Figure 5 General pulse sequence diagram for a CEST MRI experiment.](/cms/asset/c4331995-f1bd-4c6a-adaf-9ef984d830ac/dbct_a_23154619_f0005_b.jpg)
Figure 6 Example z-spectra arising from a CEST MRI experiment at 3 T.
Abbreviations: CEST MRI, chemical exchange saturation transfer magnetic resonance imaging; S, signal intensity with saturation; S0, signal intensity in the absence of saturation.
![Figure 6 Example z-spectra arising from a CEST MRI experiment at 3 T.](/cms/asset/2cd1b187-6ec3-40fe-bdf5-c84a5ccefff8/dbct_a_23154619_f0006_b.jpg)
Figure 7 Amide proton transfer (APT) maps derived from CEST MRI in breast cancer patients undergoing NAT. Baseline (pretreatment) images are presented on the left, and images after one cycle of NAT are presented on the right. (A): patient with complete response after one cycle of therapy (27% decrease in measured APT from baseline). (B): patient with partial response (49% increase in measured APT). (C): patient with progressive disease (78% increase in measured APT).
![Figure 7 Amide proton transfer (APT) maps derived from CEST MRI in breast cancer patients undergoing NAT. Baseline (pretreatment) images are presented on the left, and images after one cycle of NAT are presented on the right. (A): patient with complete response after one cycle of therapy (27% decrease in measured APT from baseline). (B): patient with partial response (49% increase in measured APT). (C): patient with progressive disease (78% increase in measured APT).](/cms/asset/bcc9eba2-3967-4826-ad94-372259d5f55b/dbct_a_23154619_f0007_c.jpg)
Figure 8 Static MRE (MIE) results from a breast cancer patient. (A) undeformed image volume. (B) deformed image volume. (C) undeformed central slice. (D) deformed central slice. (E) reconstructed tissue elasticity map.
![Figure 8 Static MRE (MIE) results from a breast cancer patient. (A) undeformed image volume. (B) deformed image volume. (C) undeformed central slice. (D) deformed central slice. (E) reconstructed tissue elasticity map.](/cms/asset/116b2e57-9c26-4864-bf67-f8b3b051efff/dbct_a_23154619_f0008_c.jpg)